AU2014289663B2 - Cystobactamides - Google Patents

Cystobactamides Download PDF

Info

Publication number
AU2014289663B2
AU2014289663B2 AU2014289663A AU2014289663A AU2014289663B2 AU 2014289663 B2 AU2014289663 B2 AU 2014289663B2 AU 2014289663 A AU2014289663 A AU 2014289663A AU 2014289663 A AU2014289663 A AU 2014289663A AU 2014289663 B2 AU2014289663 B2 AU 2014289663B2
Authority
AU
Australia
Prior art keywords
group
alkyl
formula
cystobactamide
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014289663A
Other languages
English (en)
Other versions
AU2014289663A1 (en
Inventor
Sascha Baumann
Walid A. M. Elgaher
Klaus Gerth
Franziska Gille
Mostafa Hamed
Rolf Hartmann
Jennifer HERRMANN
Stephan HUETTEL
Andreas Kirschning
Kathrin MOHR
Maria Moreno
Rolf Muller
Ritesh RAJU
Heinrich Steinmetz
Liang Liang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Publication of AU2014289663A1 publication Critical patent/AU2014289663A1/en
Assigned to HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH reassignment HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Request for Assignment Assignors: GOTTFRIED WILHELM LEIBNIZ UNIVERSITAT HANNOVER, HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Application granted granted Critical
Publication of AU2014289663B2 publication Critical patent/AU2014289663B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/02Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2014289663A 2013-07-12 2014-07-14 Cystobactamides Active AU2014289663B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003539 2013-07-12
EP13003539.7 2013-07-12
PCT/EP2014/001925 WO2015003816A2 (en) 2013-07-12 2014-07-14 Cystobactamides

Publications (2)

Publication Number Publication Date
AU2014289663A1 AU2014289663A1 (en) 2016-02-04
AU2014289663B2 true AU2014289663B2 (en) 2019-03-07

Family

ID=48792948

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014289663A Active AU2014289663B2 (en) 2013-07-12 2014-07-14 Cystobactamides

Country Status (7)

Country Link
US (3) US20160145304A1 (enExample)
EP (1) EP3019615B1 (enExample)
JP (1) JP6730183B2 (enExample)
CN (1) CN105793424B (enExample)
AU (1) AU2014289663B2 (enExample)
CA (1) CA2917767C (enExample)
WO (1) WO2015003816A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793424B (zh) 2013-07-12 2021-02-19 亥姆霍兹感染研究中心有限公司 孢囊菌酰胺
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
KR101747702B1 (ko) * 2014-05-15 2017-06-19 한국생명공학연구원 신규한 항균성 화합물 및 이의 용도
AU2015353077B2 (en) * 2014-11-26 2020-03-05 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Novel cystobactamides
CN105712894A (zh) * 2016-03-23 2016-06-29 叶芳 一种3-甲氧基-4-氨基苯甲酸及其制备方法
JP7037122B2 (ja) * 2016-09-28 2022-03-16 日産化学株式会社 ジアミンおよびその利用
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
EP3655394B1 (en) * 2017-07-18 2023-11-22 Technische Universität Berlin Novel albicidin derivatives, their use and synthesis
JP7244493B2 (ja) * 2017-08-23 2023-03-22 ヘルムホルツ-ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー 新規なシストバクタミド誘導体
ES2950757T3 (es) 2017-10-06 2023-10-13 Forma Therapeutics Inc Inhibición de la peptidasa específica de la ubiquitina 30
AU2019207616A1 (en) 2018-01-10 2020-07-09 Recurium Ip Holdings, Llc Benzamide compounds
JP7062792B2 (ja) 2018-02-13 2022-05-06 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020021921A2 (pt) 2018-05-17 2021-01-26 Forma Therapeutics, Inc. compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US12428382B2 (en) * 2021-03-31 2025-09-30 Medibeacon Inc. Purification of substituted diaminopyrazine dicarboxylic acids
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CN113563220B (zh) * 2021-06-25 2023-08-29 华中农业大学 一种抗菌化合物及其应用
WO2025003147A1 (en) 2023-06-26 2025-01-02 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamid derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525354A (en) * 1983-09-14 1985-06-25 University Of Hawaii Antibiotic and process for the production thereof
US7020622B1 (en) * 1997-06-10 2006-03-28 Linkshare Corporation Transaction tracking, managing, assessment, and auditing data processing system and network
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
ATE309369T1 (de) * 2000-04-28 2005-11-15 Kosan Biosciences Inc Heterologe herstellung von polyketiden
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
AU2003286498A1 (en) * 2002-10-18 2004-05-04 Centre De Cooperation Internationale En Recherche Agronomique Pour Le Developpement (Cirad) Complete biosynthetic gene set for biosynthesis of albicidin, resistance genes, and uses thereof
WO2006109846A1 (ja) 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
JP5379965B2 (ja) * 2006-09-26 2013-12-25 株式会社半導体エネルギー研究所 スチルベン誘導体、発光素子および発光装置
US7758972B2 (en) * 2006-09-26 2010-07-20 Semiconductor Energy Laboratory Co., Ltd. Stilbene derivative, light emitting element, light emitting device, and electronic appliance
WO2008112938A2 (en) * 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
US8236983B2 (en) * 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
WO2013078277A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
EP2956437B1 (en) * 2013-02-15 2023-05-10 Technische Universität Berlin Albicidin derivatives for the treatment of bacterial infections
CN105793424B (zh) * 2013-07-12 2021-02-19 亥姆霍兹感染研究中心有限公司 孢囊菌酰胺
KR101747702B1 (ko) 2014-05-15 2017-06-19 한국생명공학연구원 신규한 항균성 화합물 및 이의 용도
AU2015353077B2 (en) * 2014-11-26 2020-03-05 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Novel cystobactamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, vol. 55, no. 11, pages 5043 - 5053 *

Also Published As

Publication number Publication date
US20200331964A1 (en) 2020-10-22
JP6730183B2 (ja) 2020-07-29
EP3019615A2 (en) 2016-05-18
WO2015003816A3 (en) 2015-03-12
US10793600B2 (en) 2020-10-06
US11225503B2 (en) 2022-01-18
US20160145304A1 (en) 2016-05-26
CA2917767C (en) 2022-05-03
CN105793424A (zh) 2016-07-20
CN105793424B (zh) 2021-02-19
JP2016527215A (ja) 2016-09-08
EP3019615B1 (en) 2021-04-07
US20190185514A1 (en) 2019-06-20
AU2014289663A1 (en) 2016-02-04
WO2015003816A2 (en) 2015-01-15
CA2917767A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
US11225503B2 (en) Crystobactamides
US20090263886A1 (en) Farnesyl dibenzodiazepinone and processes for its production
KR100420238B1 (ko) 스트렙토그라민 및 돌연변이합성에 의한 이의 제조 방법
CN107001241B (zh) 新型孢囊菌酰胺
JP2010535481A (ja) チオペプチド前駆体タンパク質、それをコードする遺伝子およびそれらの使用
WO2012029811A1 (ja) リベロマイシンaまたはその合成中間体の製造法、スピロケタール環含有化合物の製造方法、並びに新規抗癌剤、抗真菌剤および骨疾患治療剤
US9630911B2 (en) Genes for biosynthesis of tetracycline compounds and uses thereof
Gromyko et al. Generation of Streptomyces globisporus SMY622 strain with increased landomycin E production and it's initial characterization
HK1229840B (en) Cystobactamides
CN105755076B (zh) 利用突变合成获得sansanmycin结构类似物的方法
CN117642417A (zh) 新型达罗巴汀衍生物
CA2538147A1 (en) Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
Bell Analysis and manipulation of “actagardine” gene clusters from Actinoplanes

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Free format text: FORMER APPLICANT(S): HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH; GOTTFRIED WILHELM LEIBNIZ UNIVERSITAT HANNOVER

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BAUMANN, SASCHA; HERRMANN, JENNIFER; MOHR, KATHRIN; STEINMETZ, HEINRICH; GERTH, KLAUS; RAJU, RITESH; MULLER, ROLF; HARTMANN, ROLF; HAMED, MOSTAFA; ELGAHER, WALID A. M.; MORENO, MARIA; GILLE, FRANZISKA; WANG, LIANG LIANG; KIRSCHNING, ANDREAS AND HUETTEL, STEPHAN

FGA Letters patent sealed or granted (standard patent)